Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 Aug 18;101(4):738-40.
doi: 10.1038/sj.bjc.6605207. Epub 2009 Jul 21.

Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'

H-A Hou, L-I Lin, C-Y Chen, H-F Tien
Comment

Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'

H-A Hou et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves of overall survival (OS) stratified by different status of CEBPA mutation at diagnosis among total patients (A) and in the subgroup of patients with normal karyotype (B). Only patients receiving standard chemotherapy were enrolled into survival analysis. Among total patients, P-value for OS of CEBPAdouble-mut vs CEBPAwild patients was 0.013, for CEBPAdouble-mut vs CEBPAsingle-mut patients, 0.001, and among three groups, 0.007 (A). In the subgroup of patients with normal karyotype, P-value for OS of CEBPAdouble-mut vs CEBPAwild patients was 0.01, for CEBPAdouble-mut vs CEBPAsingle-mut patients was 0.002 and among three groups it was 0.005 (B).
Figure 2
Figure 2
Kaplan–Meier survival curves of overall survival (OS) in the CEBPAsingle−mut patients with and without concurrent FLT3/ITD, FLT3/TKD, MLL/PTD or AML1/RUNX1 mutation.
See this image and copyright information in PMC

Comment on

References

    1. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103(6): 2316–2324 - PubMed
    1. Hou HA, Chou WC, Lin LI, Chen CY, Tang JL, Tseng MH, Huang CF, Chiou RJ, Lee FY, Liu MC, Tien HF (2008) Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia 22(5): 1075–1078 - PubMed
    1. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4): 1372–1379 - PubMed
    1. Pabst T, Eyholzer M, Fos J, Mueller BU (2009) Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 100(8): 1343–1346 - PMC - PubMed
    1. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15(8): 1161–1164 - PubMed

Substances